Chiasma (NASDAQ: CHMA) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Insider and Institutional Ownership
50.4% of Chiasma shares are owned by institutional investors. Comparatively, 84.4% of Anika Therapeutics shares are owned by institutional investors. 3.8% of Chiasma shares are owned by company insiders. Comparatively, 6.6% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Chiasma and Anika Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Chiasma has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.
Valuation and Earnings
This table compares Chiasma and Anika Therapeutics’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Anika Therapeutics has higher revenue and earnings than Chiasma. Chiasma is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Chiasma and Anika Therapeutics, as provided by MarketBeat.com.
||Strong Buy Ratings
Anika Therapeutics has a consensus price target of $57.00, suggesting a potential upside of 2.37%. Given Anika Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than Chiasma.
Anika Therapeutics beats Chiasma on 12 of the 12 factors compared between the two stocks.
Chiasma Company Profile
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.